Effect of Empagliflozin, a Selective Sodium-Glucose Cotransporter 2 Inhibitor, on Kidney and Peripheral Nerves in Streptozotocin-Induced Diabetic Rats.
- Author:
Kyung Ae LEE
1
;
Heung Yong JIN
;
Na Young LEE
;
Yu Ji KIM
;
Tae Sun PARK
Author Information
- Publication Type:Brief Communication
- Keywords: Diabetes mellitus, experimental; Diabetic nephropathies; Diabetic neuropathies; Peripheral nerves; Sodium-glucose transporter 2
- MeSH: Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Diabetic Neuropathies; Hypersensitivity; Kidney*; Nerve Fibers; Peripheral Nerves*; Peripheral Nervous System Diseases; Rats*; Skin; Sodium-Glucose Transporter 2; Streptozocin; Therapeutic Uses
- From:Diabetes & Metabolism Journal 2018;42(4):338-342
- CountryRepublic of Korea
- Language:English
- Abstract: The effect of sodium-glucose cotransporter 2 inhibitors on peripheral nerves and kidneys in diabetes mellitus (DM) remains unexplored. Therefore, this study aimed to explore the effect of empagliflozin in diabetic rats. DM in rats was induced by streptozotocin injection, and diabetic rats were treated with empagliflozin 3 or 10 mg/kg. Following 24-week treatment, response thresholds to four different stimuli were tested and found to be lower in diabetic rats than in normal rats. Empagliflozin significantly prevented hypersensitivity (P < 0.05) and the loss of skin intraepidermal nerve fibers, and mesangial matrix expansion in diabetic rats. Results of this study demonstrate the potential therapeutic effects of empagliflozin for the treatment of diabetic peripheral neuropathy and nephropathy.
